Barclays sets Cytokinetics stock overweight with $55 target

On Thursday, Barclays (LON:BARC) initiated coverage on Cytokinetics (NASDAQ:CYTK) shares with an Overweight rating and a price target of $55.00. The biotechnology company, listed on NASDAQ: CYTK, currently trading at $38 with a market capitalization of $4.5 billion, is recognized for its dedication to muscle function therapies, particularly in cardiovascular and neuromuscular diseases. According to InvestingPro data, analyst consensus remains strongly bullish, with price targets ranging from $47 to $120, suggesting significant upside potential despite the stock currently trading above its Fair Value. Barclays highlighted the potential of Cytokinetics’ leading drug candidate, aficamten, which is a myosin inhibitor currently under review for the treatment of obstructive hypertrophic cardiomyopathy (oHCM), with a Prescription Drug User Fee Act (PDUFA) date set for September 26.

The Barclays analyst expressed confidence in the approval prospects for aficamten, suggesting that it may receive a differentiated label compared to the first myosin inhibitor, Camzyos from Bristol Myers Squibb, especially after its recent label update. The differentiation is partly due to aficamten’s shorter half-life and reduced drug-drug interactions, which could lead to a dominant market share among newly diagnosed patients, according to feedback from Key Opinion Leaders (KOLs).

The analyst also anticipates a high probability of positive results from the Phase 3 MAPLE trial in oHCM, which would likely facilitate easier coverage from payors. Additionally, there is a reasonable expectation for success in the Phase 3 ACACIA trial, despite the recent failure of Camzyos in non-obstructive hypertrophic cardiomyopathy (nHCM).

Barclays foresees a gradual uptake following aficamten’s market launch but projects the total market opportunity to surpass $3 billion. The firm’s positive outlook on Cytokinetics’ stock reflects the potential of its lead asset and the company’s prospects within the cardiovascular treatment landscape. While the company reported strong revenue growth of 145% in the last twelve months, InvestingPro analysis reveals the company maintains a healthy current ratio of 6.17, indicating strong liquidity to fund its development pipeline. For deeper insights into CYTK’s financial health and growth prospects, investors can access the comprehensive Pro Research Report, available exclusively on InvestingPro, which covers over 1,400 US stocks with detailed analysis and actionable intelligence.

In other recent news, Cytokinetics has garnered attention from several analyst firms following developments in the cardiomyopathy treatment market. H.C. Wainwright reaffirmed a Buy rating with a $120 price target for Cytokinetics, expressing optimism about the company’s treatment, aficamten, in light of recent label updates to Bristol-Myers Squibb (NYSE:BMY)’s Camzyos. These updates, approved by the FDA, reduce the frequency of required echocardiograms and expand patient eligibility, potentially benefiting the broader cardiomyopathy inhibitor market, including aficamten. Stifel also maintained a Buy rating with an $87 price target, highlighting the relaxed Risk Evaluation and Mitigation Strategy (REMS) for Camzyos as a positive sign for Cytokinetics’ aficamten, which is not burdened by the same pharmacokinetic liabilities.

However, BofA Securities adjusted its price target for Cytokinetics to $54 from $62, maintaining a Neutral rating. This change follows Bristol-Myers Squibb’s announcement that its Phase 3 trial for mavacamten, targeting non-obstructive hypertrophic cardiomyopathy (nHCM), did not meet its primary endpoints. The trial’s outcome raised concerns about the class of cardiac myosin inhibitors, which includes Cytokinetics’ aficamten. Despite these concerns, analysts note differences between the trials that could lead to a successful outcome for aficamten. Investors will continue to monitor the performance and developments of both companies as they navigate the evolving cardiomyopathy treatment landscape.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.